Position in ALKS
as of Mar 31, 2026
· filed May 11, 2026
Position Value
$8,573,845
+$1,789,451 QoQ
Shares Held
242,473
0.0% QoQ
Ownership
0.145%
of shares outstanding
% of Portfolio
1.85%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
8 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ALKS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Atle Fund Management AB holds $20,388,946 across 2 Drug Manufacturers - Specialty & Generic names. ALKS ranks #2 (42.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
89,685 | $11,815,101 | |
| 2 | ALKS |
Alkermes plc.
This page
|
242,473 | $8,573,845 |
All Filings in ALKS
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $8,573,845 | 242,473 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $6,784,394 | 242,473 | Shares | Sole | 2026-02-06 | |
| 2025-09-30 | $7,586,250 | 252,875 | Shares | Sole | 2025-11-04 | |
| 2025-06-30 | $6,500,878 | 227,224 | Shares | Sole | 2025-07-14 | |
| 2025-03-31 | $7,091,969 | 214,778 | Shares | Sole | 2025-05-05 | |
| 2024-12-31 | $7,664,511 | 266,499 | Shares | Sole | 2025-02-04 | |
| 2024-09-30 | $6,622,713 | 236,610 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $1,658,080 | 68,800 | Shares | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||